Cessatech Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Cessatech han disminuido a una tasa media anual de -48.9%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 10.4% anualmente.

Información clave

-48.9%

Tasa de crecimiento de los beneficios

2.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	30.5%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	n/a
Margen neto	n/a
Próxima actualización de resultados	15 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Cessatech. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NGM:CESSA Ingresos, gastos y beneficios (DKK Millions)
Fecha	Beneficios	Gastos G+A
31 Dec 23	-27	23
30 Sep 23	-22	24
30 Jun 23	-18	22
31 Mar 23	-16	20
31 Dec 22	-15	18
30 Sep 22	-13	22
30 Jun 22	-13	20
31 Mar 22	-12	17
31 Dec 21	-12	14

Ingresos de calidad: CESSA actualmente no es rentable.

Margen de beneficios creciente: CESSA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: No hay datos suficientes para determinar si la tasa de crecimiento año a año de los beneficios de CESSA ha sido positiva en los últimos 5 años.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CESSA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CESSA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (3.8%).

Rentabilidad financiera

Alta ROE: El pasivo de CESSA supera su activo, por lo que es difícil calcular su rentabilidad financiera.

Cessatech Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Cessatech A/S to Report Q1, 2024 Results on May 15, 2024

Cessatech A/S to Report Q3, 2023 Results on Nov 16, 2023

Cessatech A/S to Report Q2, 2023 Results on Aug 24, 2023

Cessatech A/S to Report Fiscal Year 2022 Results on Mar 03, 2023

Recent updates

Cessatech A/S to Report Q1, 2024 Results on May 15, 2024

New major risk - Negative shareholders equity

Cessatech A/S, Annual General Meeting, Mar 27, 2024

New minor risk - Shareholder dilution

Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children

Cessatech A/S to Report Q3, 2023 Results on Nov 16, 2023

Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001

Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation

Cessatech A/S to Report Q2, 2023 Results on Aug 24, 2023

Cessatech A/S, Annual General Meeting, Mar 17, 2023

Cessatech A/S to Report Fiscal Year 2022 Results on Mar 03, 2023

High number of new and inexperienced directors

Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval

Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate

Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001

Cessatech A/S Expects to Report on its Bioavailability Trial 0204 Within Few Weeks

Cessatech Reports First Patient Dosed in Pharmacokinetic Trial in Children of Lead Product Candidate

Cessatech Reports Last Subject Dosed in Bioavailability Trial of Lead Product Candidate

Cessatech A/S, Annual General Meeting, Mar 26, 2021

Desglose de ingresos y gastos
Beta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Cessatech Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Cessatech A/S to Report Q1, 2024 Results on May 15, 2024

Cessatech A/S to Report Q3, 2023 Results on Nov 16, 2023

Cessatech A/S to Report Q2, 2023 Results on Aug 24, 2023

Cessatech A/S to Report Fiscal Year 2022 Results on Mar 03, 2023

Recent updates

Cessatech A/S to Report Q1, 2024 Results on May 15, 2024

New major risk - Negative shareholders equity

Cessatech A/S, Annual General Meeting, Mar 27, 2024

New minor risk - Shareholder dilution

Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children

Cessatech A/S to Report Q3, 2023 Results on Nov 16, 2023

Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001

Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation

Cessatech A/S to Report Q2, 2023 Results on Aug 24, 2023

Cessatech A/S, Annual General Meeting, Mar 17, 2023

Cessatech A/S to Report Fiscal Year 2022 Results on Mar 03, 2023

High number of new and inexperienced directors

Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate

Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval

Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate

Cessatech Reports Successful Outcome of Bioavailability Trial 0204 with CT001

Cessatech A/S Expects to Report on its Bioavailability Trial 0204 Within Few Weeks

Cessatech Reports First Patient Dosed in Pharmacokinetic Trial in Children of Lead Product Candidate

Cessatech Reports Last Subject Dosed in Bioavailability Trial of Lead Product Candidate

Cessatech A/S, Annual General Meeting, Mar 26, 2021

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta